Evidence map›Paper›PMID 38956568›Full record

ArticleHealth research policy and systems2024

Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy.

Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Michael Berntgen, Mira Pavlovic, Peter Mol, Jürgen Wasem, Walter Van Dyck and 7 more

Abstract read
In one paragraph

Article in Health research policy and systems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Competencies for health technology assessment professionals: a scoping review and content analysis.International journal of technology assessment in health care · 2026
    Article
  2. Article
  3. Medicine Development and Access for Rare Diseases: Can We Do Better?Journal of inherited metabolic disease · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Francine BrinkhuisUtrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
Elaine JulianSecretariat of the European Access Academy (EAA), Hauensteinstr. 132, 4059, Basel, Switzerland. info@euaac.org.
Hendrika van den HamUtrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-0513-0894
Fabrizio GianfrateUniversity of Ferrara, Ferrara, Italy.
Valentina StrammielloEuropean Patients' Forum (EPF), Brussels, Belgium.
Michael BerntgenEuropean Medicines Agency (EMA), Amsterdam, The Netherlands.
Mira PavlovicMedicines Development and Training (MDT) Services, Paris, France.
Peter MolDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-4262-3180
Jürgen WasemInstitute for Health Care Management and Research, University of Duisburg-Essen, Essen, Germany.
Walter Van DyckHealthcare Management Centre, Vlerick Business School, Brussels, Belgium.ORCID http://orcid.org/0000-0002-2829-3779
Antonella CardoneCancer Patients Europe' (CPE), Brussels, Belgium.ORCID http://orcid.org/0000-0003-3685-1512
Christian DierksDierks + Company, Berlin, Germany.
Anja SchielNorwegian Medicines Agency (NOMA), Oslo, Norway.ORCID http://orcid.org/0000-0002-1258-4731
Renato BernardiniDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), Section of Pharmacology, University of Catania, Catania, Italy.
Oriol Solà-MoralesHiTT Foundation, International University of Catalonia-UIC, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8312-8178
Jörg Ruof *Secretariat of the European Access Academy (EAA), Hauensteinstr. 132, 4059, Basel, Switzerland.
Wim Goettsch *Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe European Regulation on Health Technology Assessment (EU HTA R), effective since January 2022, aims to harmonize and improve the efficiency of common HTA across Member States (MS), with a phased implementation from January 2025. At "midterms" of the preparation phase for the implementation of the Regulation our aim was to identify and prioritize tangible action points to move forward.

methodsDuring the 2023 Spring Convention of the European Access Academy (EAA), participants from different nationalities and stakeholder backgrounds discussed readiness and remaining challenges for the Regulation's implementation and identified and prioritized action points. For this purpose, participants were assigned to four working groups: (i) Health Policy Challenges, (ii) Stakeholder Readiness, (iii) Approach to Uncertainty and (iv) Challenges regarding Methodology. Top four action points for each working group were identified and subsequently ranked by all participants during the final plenary session.

resultsOverall "readiness" for the Regulation was perceived as neutral. Prioritized action points included the following: Health Policy, i.e. assess adjustability of MS laws and health policy processes; Stakeholders, i.e. capacity building; Uncertainty, i.e. implement HTA guidelines as living documents; Methodology, i.e. clarify the Population, Intervention, Comparator(s), Outcomes (PICO) identification process.

conclusionsAt "midterms" of the preparation phase, the focus for the months to come is on executing the tangible action points identified at EAA's Spring Convention. All action points centre around three overarching themes: harmonization and standardization, capacity building and collaboration, uncertainty management and robust data. These themes will ultimately determine the success of the EU HTA R in the long run.

Indexed as

Capacity BuildingEuropean UnionHealth PolicyStakeholder ParticipationTechnology Assessment, BiomedicalAcademies and InstitutesEuropeGovernment RegulationHumansUncertaintyAccessEUHTAHealth PolicyHealth Technology AssessmentStakeholder involvement

Identifiers

PMID38956568
PMCPMC11218320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.